|
EQS-News: ABIVAX
/ Key word(s): Half Year Results
ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT PARIS, France, September 30, 2022 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the publication of its 2022 half-year financial report. This document is available in electronic version on the website of the company () and on the website of the French financial markets authority, AMF (). ***** About Abivax () Abivax, a phase 3 clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at . Follow us on Twitter @ABIVAX_. Contacts
30.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG. |
1454659 30.09.2022 CET/CEST
